Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | JAK3 | P52333 | 5/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
| ▸ | PAK4 | O96013 | 3/20 | 0.53 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | PIM1 | P11309 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | PRKACA | P17612 | 3/20 | 0.53 |
| ▸ | FLT1 | P17948 | 3/20 | 0.53 |
| ▸ | LTK | P29376 | 3/20 | 0.53 |
| ▸ | GRK5 | P34947 | 3/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.53 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28962329 | 0.79 | KDR (0.55) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL13885310 | 0.78 | JAK2 (0.56) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL3677097 | 0.78 | L3MBTL1 (0.46) | CSF1RRETPTK2LRRK2ABL1 | |
| SCHEMBL2601265 | 0.76 | JAK2 (0.63) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL9912776 | 0.76 | MTOR (0.39) | KDR | |
| SCHEMBL3639337 | 0.76 | DYRK1A (0.44) | DYRK1ANUDT1 | |
| SCHEMBL28930241 | 0.75 | DYRK1A (0.53) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL13885309 | 0.75 | JAK2 (0.61) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL13885299 | 0.75 | JAK2 (0.63) | JAK2KDRJAK3DAPK3PRKD3 | |
| SCHEMBL13885395 | 0.75 | JAK2 (0.61) | JAK2KDRJAK3DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017135589-A9 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 삼진제약주식회사 | 2017-10-19 | — | — | WO | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2170887-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | JAK2 268/4885KDR 700/4885JAK3 348/4885 |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | JAK2 16/4885KDR 2/4885JAK3 130/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | JAK2 16/4885KDR 2/4885JAK3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.